Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 11/20 | 1.00 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL700760 | 1.00 | NFE2L2 (1.00) | NFE2L2MAOBCYP19A1MAOAAPP | |
| SCHEMBL4946969 | 1.00 | NFE2L2 (1.00) | NFE2L2MAOBCYP19A1MAOAAPP | |
| SCHEMBL18867936 | 1.00 | NFE2L2 (1.00) | NFE2L2MAOBCYP19A1MAOAAPP | |
| SCHEMBL13766558 | 0.88 | NFE2L2 (0.78) | NFE2L2APPPTGS1 | |
| SCHEMBL13766470 | 0.88 | NFE2L2 (0.78) | NFE2L2APPPTGS1 | |
| SCHEMBL700052 | 0.88 | NFE2L2 (0.78) | NFE2L2APPPTGS1 | |
| SCHEMBL700051 | 0.88 | NFE2L2 (0.78) | NFE2L2APPPTGS1 | |
| SCHEMBL22468800 | 0.88 | NFE2L2 (0.78) | NFE2L2APPPTGS1 | |
| SCHEMBL11547655 | 0.85 | NFE2L2 (0.72) | NFE2L2MAOBCYP19A1MAOARELA | |
| SCHEMBL44504 | 0.85 | NFE2L2 (0.72) | NFE2L2MAOBCYP19A1MAOARELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117417372-A | Preparation method of nickel-catalyzed aromatic phosphine oxide compound | 中南大学 | 2024-01-19 | — | — | CN | claimed |
| EP-1043793-B1 | Secondary battery | MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) | 2008-04-02 | — | — | EP | claimed |
| US-6303250-B1 | BATTERIES USING NONAQUEOUS ELECTROLYTIC SOLUTION; HIGH TEMPERATURE STORAGE | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2001-10-16 | — | — | US | claimed |
| EP-1043793-A2 | Secondary battery | Matsushita Electric Industrial Co., Ltd. (JP) | 2000-10-11 | — | — | EP | claimed |
| CN-117417372-A | Preparation method of nickel-catalyzed aromatic phosphine oxide compound | 中南大学 | 2024-01-19 | — | — | CN | disclosed |
| CN-114163313-B | Method for selectively synthesizing EZ-stilbene by coupling ruthenium-catalyzed aryl diazonium salt with cinnamic acid | 中山大学 | 2023-11-03 | — | — | CN | disclosed |
| CN-113788733-A | Deuterated method of trans-olefin | 五邑大学 | 2021-12-14 | — | — | CN | disclosed |
| WO-2021074275-A1 | EFFECTIVE PHOTOMODULATION OF LANTHANIDE (III) ION LUMINESCENCE IN THE VISIBLE OR NEAR-INFRARED RANGE | UNIVERSITE DE RENNES 1 (FR) | 2021-04-22 | — | — | WO | disclosed |
| CN-106832083-B | Fluorine-containing syndiotactic polystyrene and preparation method thereof | 中国科学院长春应用化学研究所 | 2020-11-10 | — | — | CN | disclosed |
| US-9925153-B2 | Therapeutic agents for skin diseases and conditions | STC.UNM (US) | 2018-03-27 | — | — | US | disclosed |
| US-9868873-B2 | Photochromic security enabled ink for digital offset printing applications | XEROX CORPORATION (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160287531-A1 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | STC.UNM | 2016-10-06 | — | — | US | disclosed |
| EP-1043793-A2 | Secondary battery | Matsushita Electric Industrial Co., Ltd. (JP) | 2000-10-11 | — | — | EP | disclosed |
| EP-0668390-B1 | Process of enhanced chemical bonding by electron beam radiation | KIMBERLY CLARK CO (US) | 1999-11-03 | — | — | EP | disclosed |
| US-5759729-A | A DRY TONER COMPRISING A RESIN, PHOTOCHROMATIC SPIROPYRAN, -OXAZINE OR -THIOPYRAN DYE AND A CHARGE CONTROL AGENT;ELECTROGRAPHY; XEROGRAPHY | XEROX CORPORATION (US) | 1998-06-02 | — | — | US | disclosed |
| US-5710420-A | Method for embedding and recovering machine-readable information | XEROX CORPORATION (US) | 1998-01-20 | — | — | US | disclosed |
| US-5633109-A | Ink compositions with liposomes containing photochromic compounds | XEROX CORPORATION (US) | 1997-05-27 | — | — | US | disclosed |
| US-5593486-A | Photochromic hot melt ink compositions | XEROX CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| US-5551973-A | LIQUID CRYSTAL GEL PHASE, MICROEMULSION PHASE | XEROX CORPORATION (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0668390-A2 | Process of enhanced chemical bonding by electron beam radiation | KIMBERLY-CLARK CORPORATION (US) | 1995-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287531-A1 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | CUTA, TSLP, ELANE | NFE2L2 696/4885MAOB 961/4885CYP19A1 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.